Vimarsana
Biggest News Aggregation in the World

Page 39 - Nuclear Export News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nuclear Export. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nuclear Export Today - Breaking & Trending Today

Karyopharm and Menarini Group Enter into Exclusive License Agreement to Commercialize NEXPOVIO® (selinexor) in Europe and Other Key Global Territories - Vimarsana News

Karyopharm and Menarini Group Enter into Exclusive License Agreement to Commercialize NEXPOVIO® (selinexor) in Europe and Other Key Global Territories

Published: December 21, 2021

- Menarini Group Obtains Exclusive Rights to Commercialize NEXPOVIO for the Treatment of Hematologic and Solid Tumor Oncology Indications in Europe

Source: adnkronos.com
Related Topics:
United StatesUnited KingdomRichard PaulsonElcin Barker ErgunSelective Inhibitor Of Nuclear ExportKaryopharm Therapeutics IncMenarini Group Obtains Exclusive Rights To CommercializeEuropean CommissionDrug AdministrationPrnewswire Karyopharm Therapeutics IncExchange CommissionEuropean UnionMenarini GroupKaryopharm Selective Inhibitor Of Nuclear ExportEuropean Medicines AgencyCommittee For Medicinal Products Human UseGroup Obtains Exclusive RightsSolid Tumor Oncology IndicationsLatin AmericaFuture MilestonesPlus TieredDouble Digit RoyaltiesNet SalesSelective InhibitorNuclear Export
Karyopharm's Partner Antengene Receives Approval in China for XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma - Vimarsana News

Karyopharm's Partner Antengene Receives Approval in China for XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Published: December 17, 2021

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

Source: prnewswire.com
Related Topics:
United StatesRichard PaulsonAsia PacificSelective Inhibitor Of Nuclear ExportKaryopharm Therapeutics IncEuropean CommissionAntengene CorporationDrug AdministrationExchange CommissionChina National Medical Products AdministrationKaryopharm Selective Inhibitor Of Nuclear ExportEuropean UnionInformation DepartmentKaryopharm TherapeuticsChief Executive OfficerSelective InhibitorNuclear ExportNew Drug ApplicationMedical InformationFetal ToxicityPrivate Securities Litigation Reform ActQuarterly ReportKaryopharm Therapeutics Inc
Antengene Announces NDA Approval by NMPA for XPOVIO®, China's First XPO1 inhibitor, for the Treatment of Adults with Relapsed or Refractory Multiple Myeloma - Vimarsana News

Antengene Announces NDA Approval by NMPA for XPOVIO®, China's First XPO1 inhibitor, for the Treatment of Adults with Relapsed or Refractory Multiple Myeloma

Published: December 17, 2021

/PRNewswire/ -- Antengene Corporation Limited (the "Company" or "Antengene") is pleased to announce that ATG-010 (selinexor, brand name: XPOVIO®), a...

Source: prnewswire.com
Related Topics:
United StatesHong KongUnited KingdomSouth KoreaKevin LynchJay MeiAsia PacificPeter QianSelective Inhibitor Of Nuclear ExportKaryopharm Therapeutics IncAntengene CorporationInternational Myeloma Working GroupDrug AdministrationSelective Inhibitor Of NuclearAntengene Corporation LimitedNational Medical Products AdministrationEuropean Society For Medical OncologyNational Comprehensive Cancer NetworkChinese Society Of Clinical OncologyCorporation LimitedSelective InhibitorNuclear ExportChina Standard TimeChief Executive OfficerChinese Society
Antengene Announces NDA Approval by NMPA for XPOVIO®, China's First XPO1 inhibitor, for the Treatment of Adults with Relapsed or Refractory Multiple Myeloma - Vimarsana News

Antengene Announces NDA Approval by NMPA for XPOVIO®, China's First XPO1 inhibitor, for the Treatment of Adults with Relapsed or Refractory Multiple Myeloma

Published: December 17, 2021

/PRNewswire/ -- Antengene Corporation Limited (the "Company" or "Antengene") is pleased to announce that ATG-010 (selinexor, brand name: XPOVIO®), a...

Source: prnewswire.com
Related Topics:
United StatesHong KongUnited KingdomSouth KoreaKevin LynchJay MeiAsia PacificPeter QianSelective Inhibitor Of Nuclear ExportKaryopharm Therapeutics IncAntengene CorporationInternational Myeloma Working GroupDrug AdministrationSelective Inhibitor Of NuclearAntengene Corporation LimitedNational Medical Products AdministrationEuropean Society For Medical OncologyNational Comprehensive Cancer NetworkChinese Society Of Clinical OncologyCorporation LimitedSelective InhibitorNuclear ExportChina Standard TimeChief Executive OfficerChinese Society
Antengene Presents Results of Phase 1b TOUCH Trial of Selinexor for the Treatment of T and NK-Cell Lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting - Vimarsana News

Antengene Presents Results of Phase 1b TOUCH Trial of Selinexor for the Treatment of T and NK-Cell Lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting

Published: December 14, 2021

/PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering,...

Source: prnewswire.com
Related Topics:
United StatesGeorgia World Congress CenterSouth KoreaHuiqiang HuangKevin LynchJay MeiAsia PacificPeter QianKaryopharm Press Release On NovKaryopharm Therapeutics IncAntengene CorporationSun Yat Sen University Affiliated Cancer HospitalDrug AdministrationSelective Inhibitor Of NuclearAntengene Corporation LimitedLymphoma CenterChief Medical OfficerChief Executive OfficerHeavily Pretreated PatientsPeripheralt Cell LymphomaT Cell LymphomaPreliminary ResultsSingle Arm Phase Ib StudyGeorgia World CongressKaryopharm Therapeutics